RxSight Past Earnings Performance
Past criteria checks 0/6
RxSight's earnings have been declining at an average annual rate of -50.9%, while the Medical Equipment industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 60.5% per year.
Key information
-50.9%
Earnings growth rate
-67.1%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 60.5% |
Return on equity | -27.1% |
Net Margin | -44.0% |
Next Earnings Update | 05 Aug 2024 |
Recent past performance updates
Recent updates
Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12RxSight: First And Only Customizable Intraocular Lens
Aug 26Revenue & Expenses Breakdown
How RxSight makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 101 | -44 | 82 | 30 |
31 Dec 23 | 89 | -49 | 75 | 29 |
30 Sep 23 | 77 | -55 | 70 | 28 |
30 Jun 23 | 67 | -59 | 65 | 27 |
31 Mar 23 | 58 | -62 | 62 | 26 |
31 Dec 22 | 49 | -67 | 59 | 26 |
30 Sep 22 | 41 | -67 | 55 | 25 |
30 Jun 22 | 35 | -63 | 49 | 24 |
31 Mar 22 | 28 | -59 | 41 | 24 |
31 Dec 21 | 23 | -49 | 33 | 24 |
30 Sep 21 | 19 | -15 | 26 | 24 |
30 Jun 21 | 17 | 4 | 21 | 24 |
31 Mar 21 | 15 | 17 | 17 | 23 |
31 Dec 20 | 15 | 3 | 15 | 22 |
31 Dec 19 | 2 | 26 | 15 | 30 |
Quality Earnings: RXST is currently unprofitable.
Growing Profit Margin: RXST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RXST is unprofitable, and losses have increased over the past 5 years at a rate of 50.9% per year.
Accelerating Growth: Unable to compare RXST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RXST is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.5%).
Return on Equity
High ROE: RXST has a negative Return on Equity (-27.14%), as it is currently unprofitable.